Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 6/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | STAT3 | P40763 | 2/20 | 0.42 |
| ▸ | RHEB | Q15382 | 3/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ATP4A | P20648 | 1/20 | 0.37 |
| ▸ | ATP4B | P51164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8283857 | 0.89 | CSF1R (0.57) | CSF1RHTTRHEBPOLB | |
| SCHEMBL12884198 | 0.87 | CSF1R (0.42) | CSF1RHTTSMN1; SMN2STAT3RHEB | |
| SCHEMBL12884191 | 0.86 | CSF1R (0.40) | CSF1RHTTSMN1; SMN2STAT3RHEB | |
| SCHEMBL12884203 | 0.86 | CSF1R (0.43) | CSF1RHTTSMN1; SMN2STAT3RHEB | |
| SCHEMBL12884202 | 0.86 | CSF1R (0.43) | CSF1RHTTSMN1; SMN2STAT3RHEB | |
| SCHEMBL8252433 | 0.85 | S1PR4 (0.36) | MAPTKDM4E | |
| SCHEMBL12884187 | 0.84 | CYP1A2 (0.53) | CSF1RHTTSMN1; SMN2LMNAMAPT | |
| SCHEMBL8286215 | 0.81 | CSF1R (0.57) | CSF1RHTTPOLB | |
| SCHEMBL8242386 | 0.81 | KDM4E (0.48) | ACSS2MAPTKDM4E | |
| SCHEMBL8286213 | 0.76 | CSF1R (0.53) | CSF1RHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884215-B2 | 2-substituted benzimidazoles | JANSSEN SCIENCES IRELAND UC (IE) | 2011-02-08 | — | — | US | disclosed |
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100092426-A1 | 2-SUBSTITUTED BENZIMIDAZOLES | HTR4, HRH4, HTR3C | CSF1R 4057/4885HTT 1139/4885SMN1; SMN2 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.